| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
PW0787 targets GPR52, an orphan G protein-coupled receptor. GPR52 is predominantly expressed in the brain and has been implicated in the regulation of psychostimulant behavior. PW0787 functions as a potent and selective GPR52 agonist. It is brain-penetrant and orally active, making it a valuable tool for in vivo studies.
|
|---|---|
| ln Vitro |
In vitro, PW0787 is a potent GPR52 agonist with an EC50 of 135 nM. It demonstrates selectivity for GPR52 and brain penetrance. The compound's agonistic activity has been characterized in cell-based functional assays measuring downstream signaling such as cAMP accumulation.
|
| ln Vivo |
PW0787 (0.3, 1, 3 or 10 mg/kg; IP) displays antipsychotic-like activity by significantly inhibiting amphetamine-induced hyperlocomotor behavior in mice [1]. PW0787 was evaluated in rats following a single oral (PO) dose of 20 mg/kg or intravenous (IV) administration of 10 mg/kg. PW0787 has excellent plasma exposure after PO (AUC0-inf = 13,749 ng·h/mL) and IV administration (AUC0-inf=9030 ng·h/mL), as well as high post-PO maximum serum concentration (Cmax= 3407 ng/mL). mL) and IV administration (Cmax=6726 ng/mL). In addition, PW0787 showed good plasma volume of distribution (Vss=1.5 L/kg) and acceptable plasma clearance (CL=1.1 L/h/kg) after 10 mg/kg IV. Excellent oral bioavailability (F) was observed, with a value of 76% [1].
In vivo, PW0787 suppresses psychostimulant behavior. It is orally active and brain-penetrant, making it suitable for studying central nervous system effects. The compound has potential for research on neurological and psychiatric disorders. |
| Enzyme Assay |
The binding affinity and agonist activity of PW0787 are measured using cell-based functional assays with recombinant GPR52 protein. EC50 values are determined from dose-response curves. Typical assays measure GPR52-mediated cAMP accumulation or β-arrestin recruitment.
|
| Cell Assay |
The cellular activity of PW0787 is evaluated in GPR52-expressing cell lines. Cells are treated with the compound, and receptor activation is assessed by measuring downstream signaling or second messenger responses. cAMP levels are measured using HTRF or luminescence-based assays.
|
| Animal Protocol |
Animal/Disease Models: Naive male C57/BL6 black mouse weighing between 24 and 31 g
Doses: 0.3, 1, 3 or 10 mg/kg (dissolve in 0.9% saline containing 20% HP-β-CD, adjust solution (final pH) to 7.4) Route of Administration: IP Experimental Results: Both the 3 mg/kg and 10 mg/kg doses inhibited amphetamine (AMPH)-induced horizontal activity. In vivo efficacy of PW0787 is evaluated in animal models of psychostimulant behavior. Animals are administered the compound orally, and behavioral responses such as locomotor activity are assessed. Brain penetration is confirmed by measuring compound levels in brain tissue. |
| ADME/Pharmacokinetics |
PW0787 has a molecular formula of C23H20F4N4O2 and a molecular weight of 460.42 g/mol. It is soluble in DMSO (50 mg/mL). Purity is >98%.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for PW0787 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
PW0787 is a potent, selective, orally active, and brain-penetrant GPR52 agonist (EC50 = 135 nM). It suppresses psychostimulant behavior and is a valuable tool for studying GPR52 function and its role in neurological and psychiatric disorders.
|
| Molecular Formula |
C23H20F4N4O2
|
|---|---|
| Molecular Weight |
460.424118995667
|
| Exact Mass |
460.15
|
| Elemental Analysis |
C, 60.00; H, 4.38; F, 16.50; N, 12.17; O, 6.95
|
| CAS # |
2624131-45-7
|
| PubChem CID |
155977949
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
667
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(C2=CC=CC(=C21)C(=O)NCCO)C3=NC=NC(=C3)CC4=CC(=CC(=C4)F)C(F)(F)F
|
| InChi Key |
OLNVWBLTVAPNME-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H20F4N4O2/c24-16-9-14(8-15(11-16)23(25,26)27)10-17-12-21(30-13-29-17)31-6-4-18-19(2-1-3-20(18)31)22(33)28-5-7-32/h1-3,8-9,11-13,32H,4-7,10H2,(H,28,33)
|
| Chemical Name |
1-(6-(3-fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-N-(2-hydroxyethyl)indoline-4-carboxamide
|
| Synonyms |
PW0787; PW 0787; PW-0787;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~108.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1719 mL | 10.8596 mL | 21.7193 mL | |
| 5 mM | 0.4344 mL | 2.1719 mL | 4.3439 mL | |
| 10 mM | 0.2172 mL | 1.0860 mL | 2.1719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
